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Background
Macrophage activation syndrome (MAS) is a complica-
tion of systemic onset JIA (SOJIA), which is characterized
by fever, hepatosplenomegaly, lymphoadenopathy, pan-
cytopenia, liver dysfunction, pulmonary damage and CNS
dysfunction. We did the study to analyze the clinical fea-
tures, treatment, and outcome of MAS with SOJIA.
Materials and methods
Review of cases of MAS from a prospectively collected
database of children with SOJIA in Beijing Children's
Hospital from the year of 2003 to 2007.
Results
42 patients were diagnosed MAS with SOJIA from 159
SOJIA cases. The duration prior to MAS is 11 months.
High fever, hepatosplenomegaly, pancytopenia, liver dys-
function were in all cases. Bleeding was in 12. 45% has
had CNS dysfunction. 24% were with ARDS. 2 suffered
from renal damage. The lab.tests revealed elevated live
enzymes and ferritin, decreased value of ESR, album, CBC
and fibrinogen in all. Bone marrow examination sup-
ported the diagnosis with definite haemophagocytosis in
42 cases. Lymph node biopsy was done for one case and
found out it was filled of activated macrophage. In the
treatment, thirteen only received high dose steroids (four
of thirteen died), twenty-one got high dose steroids plus
cyclosporine (four died), five were steroids plus
cyclosporine and etoposide (none died). The causes of
death were ARDS and CNS involvement.
Conclusion
MAS is a rare and potentially fatal complication of SOJIA.
Most of our patients were male. Bone marrow studies sup-
port the diagnosis. CNS involvement and ARDS are poor
prognostic signs. Early diagnosis and aggressive therapy is
essential.
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